Aura Biosciences, Inc.
NASDAQ:AURABiotechnology
-$0.09 today
- Market cap
- $743.09M
- Beta
- 0.39
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$1.67
Volume 0.69M
Average 0.52M
AURA Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Aura Biosciences, Inc.NASDAQ: AURA
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $30M (cash outflow) rose 27.4% year over year, ahead of the +14.5% change in trailing-twelve-month free cash flow. Sequentially, it rose 45.3% from the prior quarter. Over 3 fiscal years it compounded at +15.2% a year.
Context
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +27.4% holds above the trailing-twelve-month pace of +14.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (85.19M) USD
- Year-over-year change
- -5.1%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (85.19M) | -5.1% |
| FY2024 | 2024-12-31 | (81.06M) | -25.6% |
| FY2023 | 2023-12-31 | (64.56M) | -15.9% |
| FY2022 | 2022-12-31 | (55.7M) | -61.3% |
| FY2021 | 2021-12-31 | (34.54M) | — |
Free Cash Flow vs competitors
How AURA compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +14.5% is the 7th highest of 11, against a peer median of +19.5%.
- Over three fiscal years its annual growth of +15.2% compares with a peer median of +27.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $271.54M USD | +79.5% | +53.6% | 3565.9% | |
| LTM Sep 2026 | $238.7M USD | +24.3% | +90.7% | — | |
| LTM Mar 2026 | $229.01M USD | +25.5% | +34.0% | 360.7% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $97.99M USD | +60.1% | +25.1% | 1371.4% |
| LTM Mar 2026 | $91.64M USD | +14.5% | +15.2% | — | |
| FY2025 | $73.71M USD | -719.4% | +53.4% | 1134.5% | |
| LTM Mar 2026 | $73.65M USD | +46.6% | +19.8% | — | |
| LTM Mar 2026 | $71.69M USD | -1.0% | -2.9% | 45.6% | |
| LTM Mar 2026 | CHF 62.47M CHF | +14.4% | +29.7% | 12395.4% | |
| LTM Mar 2026 | $59.58M USD | +14.7% | -4.0% | 1334.3% | |
| LTM Mar 2026 | $47.05M USD | -26.5% | -2.9% | 14121.8% | |
| Peer median (excluding AURA) | — | +19.5% | +27.4% | 1352.8% | |
Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (35.25M) | (58.76M) | (76.41M) | (86.92M) | (106.19M) |
| Depreciation & Amortization | 831K | 1.18M | 1.3M | 1.22M | 1.13M |
| Deferred Income Tax | 14K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.31M | 6.41M | 8.77M | 11.72M | 14.32M |
| Change in Working Capital | (315K) | (3.1M) | 4.44M | (2.64M) | 5.97M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.05M | 340K | (1.04M) | 482K | (846K) |
| Other Working Capital | (1.37M) | (3.44M) | 5.48M | (3.12M) | 6.82M |
| Other Non-Cash Items | 4K | (325K) | (1.95M) | (3.19M) | 32K |
| Operating Cash Flow | (32.41M) | (54.6M) | (63.85M) | (79.81M) | (84.74M) |
| Capital Expenditures | (2.13M) | (1.09M) | (709K) | (1.25M) | (447K) |
| Acquisitions (Net) | 0 | 66.78K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (119.78M) | (233.65M) | (59.11M) | (83.96M) |
| Sales of Investments | 0 | 53.01M | 120.4M | 129.18M | 120M |
| Other Investing Activities | 0 | (66.78K) | 0 | 0 | 0 |
| Investing Cash Flow | (2.13M) | (67.87M) | (113.96M) | 68.82M | 35.6M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 78.7M | 8.55M | 3.17M | 1.6M | 77.16M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 334K | 430K | 1.5M | 0 | 0 |
| Financing Cash Flow | 166.26M | 95.63M | 97.29M | 1.6M | 77.16M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (186K) |
| Net Change in Cash | 131.72M | (26.84M) | (80.52M) | (9.39M) | 27.82M |
| Free Cash Flow | (34.54M) | (55.7M) | (64.56M) | (81.06M) | (85.19M) |
Aura Biosciences, Inc.
NASDAQ:AURA
Intrinsic Alpha fair value
Locked
Current Price
$7.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.